Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

JNK-IN-8

Catalog No: tcsc0601

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:
1410880-22-6

Formula:
$C_{29}H_{29}N_7O_2$

Pathway:
MAPK/ERK Pathway

Target:
JNK

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 35 mg/mL (68.95 mM)

Observed Molecular Weight:
507.59

Product Description

JNK-IN-8 is a potent **JNK** inhibitor with **IC_{50}** of 4.7 nM, 18.7 nM, and 1 nM for **JNK1**, **JNK2**, and **JNK3**, respectively.

IC50 & Target: IC50: 4.7/18.7/1 nM (JNK1/2/3)[1]

In Vitro:

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

JNK-IN-8 inhibits phosphorylation of c-Jun, a direct substrate of JNK kinase. JNK-IN-8 inhibits c-Jun phosphorylation in HeLa and A375 cells with EC_{50} of 486 nM and 338 nM, respectively. JNK-IN-8 also exhibits exceptional selectivity based upon KinomeScan and enzymatic profiling. Cumulatively these combined profiling technologies demonstrate that both JNK-IN-8 and JNK-IN-12 are remarkably selective covalent JNK inhibitors and are appropriate for interrogating JNK-dependent biological phenomena[1]. JNK-IN-8, a selective pan-JNK inhibitor, is discovered to inhibit JNK kinase by broad-base kinase selectivity profiling of a library of acrylamide kinase inhibitors based on the structure of imatinib using the KinomeSca approach. JNK-IN-8 possess distinct regio-chemistry of the 1,4-dianiline and 1,3-aminobenzoic acid substructures relative to imatinib and uses an N,N-dimethyl butenoic actemide warhead to covalently target Cys154. JNK-IN-8 adopts an L-shaped type I binding conformation to access Cys 154 located towards the lip of the ATP-binding site[2].